<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042457</url>
  </required_header>
  <id_info>
    <org_study_id>2009-002</org_study_id>
    <nct_id>NCT01042457</nct_id>
  </id_info>
  <brief_title>Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate therapeutic response to MMF treatment in patients with International Society of
      Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis. Mycophenolic
      acid levels at 1-hour post dose will be monitored monthly up to 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of Mycophenolic acid concentration-controlled therapy in active lupus nephritis patients at 6th month</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine Mycophenolic acid level related side effect.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.</description>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 16-60 years.

          -  Ability and willingness to provide written informed consent (or to obtain consent from
             parent guardian where applicable) and to comply with the schedule of protocol
             requirements

          -  Diagnosis of SLE according to ACR criteria. At least 4 criteria must have been present
             for the diagnosis of SLE. The 4 criteria do not have to be present at the time of
             screening

          -  Active lupus nephritis defined as follows: Biopsy proven (within 16 weeks prior to
             screening) ISN Class III or IV (A or A/C) not include III(C) IV(C) and VI (&gt;90%
             chronic irreversible scarring)

        Exclusion Criteria:

        Relates to SLE

          -  Severe renal impairment as defined by calculated creatinine clearance or MDRD-GFR &lt; 30
             ml/min(except creatinine clearance or MDRD-GFR &gt; 50 ml/min in the 12 weeks prior to
             screening)

          -  History of serious disease or complication in any organ system that not appropriate to
             treatment immunosuppressive drug groups.

        Related to Treatment

          -  Previous of any Mycophenolate groups in the 3 months prior to screening.

          -  Treatment with more than 2 g Cyclophosphamide in the last 6 months period prior to
             screening.

          -  Receipt of more than 3 g IV pulse methylprednisolone within the last 3 months prior to
             screening.

          -  Receipt of prednisolone dose &gt; 30 mg/day for longer than 30 days within last 3 months
             prior to screening.

        Related to General Health

          -  Pregnancy or breast feeding mothers.

          -  Evidence of significant uncontrolled concomitant disease in any organ system not
             related to SLE.

          -  History of cancer, including solid tumors, hematological malignancies and carcinoma.

          -  History of serious recurrent or chronic infection.

          -  Evidence of current abuse of drugs or alcohol.

        Related to Laboratory Findings

          -  Neutrophile &lt; 1,500/mm3, Hb &lt; 7g/L, Platelet &lt; 50,000/mm3 (except active SLE)

          -  Positive HBsAg or anti-HCV or anti-HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingyos Avihingsanon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.lupus.research.chula.ac.th/</url>
    <description>(Lupus Research Unit)</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trough level</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Mycophenolic acid</keyword>
  <keyword>lupus nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

